Showing results (1101-1110 of 1,205) with videos related to
Sort By:
Pageof 121
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 14, 2015
Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipientsK A Newell, A Asare, I Sanz, et al.Journal of the National Comprehensive Cancer Network : JNCCN|July 13, 2022
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium StudyQuisette P Janssen, Jacob L van Dam, Laura R Prakash, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2022
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatmentFlorian E Buisman, Daniele Giardiello, Nancy E Kemeny, et al.Blood Advances|November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomasElise A Chong, Elicia Penuel, Ellen B Napier, et al.Journal of Clinical Medicine|May 11, 2024
Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive SurgeryEdward Christopher Dee, Victor C Ng, Eileen M O'Reilly, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2023
Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal AdenocarcinomaBrett L Ecker, Alice J Tao, Quisette P Janssen, et al.The Lancet. Oncology|September 4, 2022
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysisBrett L Ecker, Jasme Lee, Lily V Saadat, et al.Blood|October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLaurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II StudyLihua E Budde, Sarit Assouline, Laurie H Sehn, et al.Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 25, 2023
[Efficacy and safety of bendamustine-rituximab combination therapy for newly diagnosed indolent B-cell non-Hodgkin's lymphoma and elderly mantle cell lymphoma: a multi-center prospective phase II clinical trial in China]H Wang, Q He, D Liu, et al.Pageof 121